Kurt Andree, DMSc, PA-C, CAQ-HM
Article
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
February 2, 2026
CLINICAL QUESTION: Does oral semaglutide decrease major cardiovascular events in patients with type 2 diabetes and cardiovascular disease and/or chronic kidney disease? BACKGROUND: Approximately 828...